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Abstract
Objectives To meta-analyze complication rate in computed
tomography (CT)-guided transthoracic lung biopsy and asso-
ciated risk factors.
Methods Four databases were searched from 1/2000 to
8/2015 for studies reporting complications in CT-guided lung
biopsy. Overall and major complication rates were pooled and
compared between core biopsy and fine needle aspiration
(FNA) using the random-effects model. Risk factors for com-
plications in core biopsy and FNA were identified in meta-
regression analysis.
Results For core biopsy, 32 articles (8,133 procedures) were
included and for FNA, 17 (4,620 procedures). Pooled overall
complication rates for core biopsy and FNA were 38.8 %
(95 % CI: 34.3–43.5 %) and 24.0 % (95 % CI: 18.2–
30.8 %), respectively. Major complication rates were 5.7 %
(95 % CI: 4.4–7.4 %) and 4.4 % (95 % CI: 2.7–7.0 %), re-
spectively. Overall complication rate was higher for core
biopsy compared to FNA (p<0.001). For FNA, larger needle
diameter was a risk factor for overall complications, and in-
creased traversed lung parenchyma and smaller lesion size
were risk factors for major complications. For core biopsy,
no significant risk factors were identified.
Conclusions In CT-guided lung biopsy, minor complications
were common and occurred more often in core biopsy than
FNA. Major complication rate was low. For FNA, smaller
nodule diameter, larger needle diameter and increased tra-
versed lung parenchyma were risk factors for complications.
Key Points
• Minor complications are common in CT-guided lung biopsy
• Major complication rate is low in CT-guided lung biopsy
• CT-guided lung biopsy complications occur more often in
core biopsy than FNA
• Major complication rate is similar in core biopsy and FNA
• Risk factors for FNA are larger needle diameter, smaller
lesion size
Keywords Lung neoplasms .Meta-analysis . Biopsy .
Pneumothorax . Computed tomography, X-Ray
Abbreviations
95 % CI 95 % Confidence interval
CT Computed tomography
FNA Fine needle aspiration
NOS Newcastle Ottawa scale
OR Odds ratio
SIR Society of Interventional Radiology
Introduction
In the US, lung cancer screening by low-dose computed to-
mography (CT) is recommended for people at high risk [1],
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and the European Society of Radiology and the European
Respiratory Society have recently recommended lung cancer
screening within clinical trial setting or in routine clinical
practice at certified medical centers [2]. This development will
cause an increase in CT-detected lung nodules. Nodules
>10 mm and most likely even smaller nodules with high
growth rate will be eligible for medical work-up, including
CT-guided lung biopsy [2]. CT-guided transthoracic lung bi-
opsy is a minimally invasive diagnostic procedure for tissue
diagnosis of peripheral lung nodules. This can alternatively be
achieved by surgery, but CT-guided transthoracic lung biopsy
is less invasive and associated with lower costs.
CT-guided transthoracic lung biopsy is a widely accepted
procedure [3, 4], although the reported complication rate
varies greatly. Where some papers report a higher complica-
tion rate for core needle biopsy compared to fine needle aspi-
ration (FNA) [5, 6], other studies [7, 8] do not. Yao et al. [9]
concluded in a systematic review comparing FNA with core
biopsy that no significant difference in complication rate be-
tween these techniques exists. They also concluded that core
biopsy is generally reported to have a somewhat higher diag-
nostic performance compared to FNA, especially in identify-
ing histological subtypes; the evidence is insufficient to sup-
port a difference.
Complication rate and diagnostic performance are the two
main factors in choosing a diagnostic procedure. To determine
the role of CT-guided transthoracic lung biopsy in the work-up
of screen-detected lung nodules, it is imperative to know how
safe the procedure is. We conducted this meta-analysis to 1)
determine the complication rate, and 2) identify risk factors for
complications of CT-guided core biopsy and FNA.
Materials and methods
This study was conducted according to the PRISMA guide-
lines for systematic reviews and meta-analyses [10].
Search strategy and study selection
A literature research was performed from January 2000 to
August 21, 2015, on PubMed, Embase, Web of Science, and
the Cochrane Library using variations of the combination of
the following search terms: (biopsy OR FNA) AND
(transthoracic OR CT-guided) AND (lung cancer) AND CT.
Please see e-Table 1 for the set of search terms per database.
After screening title and abstract, two reviewers (W.H., G.J.)
evaluated the full text of the remaining articles, with disagree-
ments resolved by consensus.
Inclusion criteria were: (a) reporting of complications of at
least 50 procedures; (b) differentiation in complications be-
tween core biopsy and FNA if both techniques were used;
(c) the study was not a subset of patients from other included
studies; (d) adequate complication monitoring. Complication
monitoring was considered adequate if directly following the
procedure a CT scan was acquired, plus a CT scan or chest
radiograph 2 to 4 h after the procedure. Studies were excluded
during screening if they clearly addressed a different topic,
were case reports, conference abstracts, reviews or editorials,
or if they were not published in English.
A standardized extraction form was used to collect the
characteristics of the study regarding patients, nodules, proce-
dures and complications, and how complication monitoring
was performed. Two authors (W.H., G.J.) independently ex-
tracted these data, with disagreement resolved by consensus.
The database was split according to the biopsymethod, and all
analyses were performed separately for core biopsy and FNA.
The methodological quality of the studies was assessed
using the Newcastle-Ottawa Scale for nonrandomized studies,
with results in a score of 0 to 9 [11]. Two authors (W.H., G.J.)
independently scored the studies, with disagreement resolved
by consensus.
Complications were classified as minor or major according
to the Society of Interventional Radiology (SIR) Guidelines
[12].Minor complications consisted of pneumothorax without
need for intervention, ground glass opacity around the target
diagnosed as pulmonary hemorrhage, and transient hemopty-
sis. Major complications consisted of pneumothorax requiring
intervention, hemothorax, air embolism, needle tract seeding,
and death. Intervention was defined as treatment conse-
quences (manual aspiration, chest tube placement, or pain
control) or hospital admission. For each study the number of
(major) complications was determined as the sum of all re-
ported (major) complications. If the complications for differ-
ent subgroups were reported, the number of (major) compli-
cations was determined per subgroup.
Study-specific risk factors for overall complications and for
major complications that were examined are listed in Table 1.
Data analysis
Heterogeneity in the overall complication rate between studies
was tested and quantified using the I2 index [13]. I2 values of
0, 25, 50, and 75 % were defined as no, low, moderate, and
high heterogeneity, respectively. To identify sources of hetero-
geneity, the effect of potential risk factors on between-study
heterogeneity was investigated. The R2 equivalent was deter-
mined to express the true variance explained by the model, as
a proportion of the total true variance. The risk of publication
bias was visually assessed with funnel plots of major compli-
cation rate against the sample size of the individual studies.
Pooled complication rates for core biopsy and FNA were
calculated using the random-effects model, weighted by the
inverse variance of the studies, under the assumption of het-
erogeneity. Across subgroups, a common among-study vari-
ance component was assumed, and subgroups were combined
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using a fixed effect model. Forest plots were made for ma-
jor complications and for all types of complications sepa-
rately. Differences in complication rate between core biop-
sy and FNA procedures were assessed using regression
analysis. All recorded study, patient, nodule, and procedur-
al characteristics as listed in Table 1 were analyzed as po-
tential risk factors for overall complications and for major
complications in regression analysis. Correlations with sig-
nificance level of p > 0.10 are presented with odds ratio
(OR) and 95 % confidence interval (95 % CI). Statistical
significance was set at p< 0.05. All statistical analyses were
conducted with Comprehensive Meta-Analysis (CMA,
version 3.2.070).
Results
Figure 1 shows the PRISMA flow diagram. Thirty-two in-
cluded studies reported complications of core biopsy and 17
of FNA. Three studies reported complications of both biopsy
techniques. Tables 2 [7, 8, 14–39] and 3 [7, 8, 40–53] show
the study characteristics, complication rates, NOS scores, and
forest plots for major complications of the studies for core
biopsy and FNA, respectively. Forest plots for all types of
complications separately can be found in e-Tables 2–9. The
median NOS scores of core biopsy and FNA studies were 8
and 7 out of 9, respectively (p=0.917). The case control stud-
ies (n=27) scored least points for representativeness of cases
(19/27) and for comparability of cases and controls (20/54).
The cohort studies (n=18) scored least points for comparabil-
ity of cohorts (26/36). Tables 3 and 4 summarizes the study,
patient, nodule, and procedural characteristics of the included
studies.
The heterogeneity between studies was high; for core bi-
opsy I2 =93.74 % (Q-value 606.5, df (Q)= 38, p<0.001) and
for FNA I2=95.3 % (Q-value 362.3, df (Q)=17, p<0.001).
For core biopsy no sources of heterogeneity were identified.
For FNA, needle diameter and nodule size were sources of
Table 1 Study-specific characteristics examined as risk factors for (major) complications
Potential risk factor Explanation
Mean nodule size Greatest axial cross section of lesion (mm)
Mean nodule depth Distance skin-lesion (mm)
Distance pleura-lesion (mm)
Mean number of biopsies Number of biopsy samples acquired per procedure
Use of coaxial needle –
Biopsy needle diameter When using coaxial needle, the coaxial needle diameter was used, as this is the outer diameter (mm)
Use of CT-fluoroscopy –
Use of biopsy site down technique Post-procedural repositioning of patients with the biopsy site facing downwards in an effort to reduce
complication rate
Presence on-site cytopathology –
Mean procedural time –
Number of operators –
Study size –
Malignancy rate Ratio of procedures in which the lesion was diagnoses as malignant by CT-guided biopsy of FNA
Operator experience If an operator experience range was mentioned, the minimal mean operator experience was determined
(i.e. four operators with 5–10 years experience resulted in a mean of 6.25 years)
Institute frequency If all procedures were performed consecutively or with a negligible number of excluded cases (<10 %), and
the inclusion start and end dates were reported, the frequency at which the procedure was performed at the
institute was determined. A distinction was made between high volume centres, with one or more
procedures per week, and low volume centres, less than one procedure per week.
Fig. 1 PRISMA flow chart of article selection process
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heterogeneity, explaining 17 and 22 % of between-study var-
iance, respectively. The funnel plots are shown in Figs. 2, 3,
and 4 showing no indication of publication bias.
Table 5 shows the pooled complication rates of core biopsy
and FNA, with respective odds ratios. Core biopsy had an
overall complication rate of 38.8 % (95 % CI: 34.3–43.5 %),
versus 24.0 % (95 % CI: 18.2–30.8 %) for FNA (p<0.001).
Respective rates for major complications were 5.7 % (95 %
CI: 4.4–7.4 %) and 4.4 % (95 % CI: 2.7–7.0 %) (p=n.s.). In
total, only five studies [30, 31, 34, 44, 50] reported cases of
hemothorax; no pooled hemothorax rate could reliably be de-
termined. Needle tract seeding, air embolism, and death were
not reported in the included studies. The overall pneumotho-
rax rate, the pulmonary haemorrhage rate, and the hemoptysis
rate of FNA procedures were significantly lower than those of
core biopsy procedures.
Table 2 Characteristics, complication rates, and forest plot for major complications from included studies for core biopsy





















Anzidei et al74 (2015) CT 0h & CXR 4h 342 18 g 36 45.3 N.S. N.S. 8 47/342
Besir et al14 (2011) CT 0h & CXR 2h 102 18 g 36 15.7% 8.8% N.S. 2.0% 7 9/102
Billich et al15 (2008) CT 0h & CXR 2h ControlNaCl plug
70













Bozbas et al16 (2010) CT 0h & CT 1h 270 19 g cx 40 21.9% 8.1% 3.3% 0.7% 6 22/270
Braak et al17 (2012) CT 0h & CXR 2h CT-ﬂuoroscopy 84 17 g cx 33 16.7% 7.1% N.S. 1.2% 7 6/84
Branden et al70 (2014) CT 0h & CXR 4h 380 16 g cx N.S. 36.1% 5.8% 10.8% N.S. 9 22/380
Chakrabar et al19 (2009) CT 0h & CXR 3h 134 19 g cx N.S. 23.9% 3.7% 3.7% 0.7% 5 5/134
Lim et al20 (2014) CT 0h & CXR 4h No pleural contactPleural contact
249




0.0% N.S. N.S. 9
7/249
0/132
Hanninen et al21 (2001) CT 0h & CXR 4h 79 20 g N.S. 24.1% 5.1% 29.1% 0.0% 7 4/79
Heck et al22 (2006) CT 0h & CXR 2h CT-ﬂuoroscopyconvenonal
57






9.5% N.S. N.S. 7
4/57
4/42
Hiraki et al23 (2010) CT 0h & CXR 3h CT-ﬂuoroscopy 1098 19 g cx 23 42.3% 5.0% N.S. N.S. 9 55/1098
Khan et al24 (2008) CT 0h & CXR 4h 135 18 g N.S. 17.0% 2.2% 27.4% 6.7% 8 3/135
Kim et al75 (2008) CT 0h & CXR 3h 50 18-20 g 19 20.0% 2.0% 26.0% 14.0% 6 1/50















Kuban et al60 (2015) CT 0h & CXR 3h 1002 18-19 g cx N.S. 30.0% 16.0% N.S. N.S. 6 156/1002
Laurent et al7 (2000) CT 0h & CXR 4-6h 98 18 g cx 35 15.3% 2.0% 28.6% 4.1% 9 2/98
Laurent et al27 (2000) CT 0h & CXR 4h Ø<2cmØ>=2cm
67













Loubeyre et al28 (2005) CT 0h & CXR 4h 76 17 g cx N.S. 15.8% 1.3% 18.4% 7.9% 8 1/76
Maataoui et al29 (2012) CT 0h & CXR 4h 135 18 g N.S. N.S. 2.2% 6.7% N.S. 6 3/135
Mendiraa-Lala et al30 (2014) CT/CTf 0h & CXR 2-4h CT-ﬂuoroscopy 169 19 g 24 40.8% 8.3% N.S. N.S. 17/169
Montaudon et al31 (2004) CT 0h & CXR 4h 605 19 g cx N.S. 17.4% 0.5% 20.2% 4.0% 7 5/605
Patel et al32 (2014) CT 0h & CXR 2h 174 19 g cx 27 36.2% 16.7% N.S. N.S. 9 29/174

















Rotolo et al76 (2015) CT 0h % CXR 4h CT-ﬂuoroscopy 201 20 g cx 17 26.7% 9.4% 18.6% 0.5% 9 19/201
Satoh et al34 (2005) CT 0h & CXR 2h 65 18-20 g 34 27.7% 1.5% 23.1% 0.0% 7 2/65
Schoth et al35 (2010) CT 0h & CXR 2h & CXR 4h 36 18 g 29 27.8% 5.6% N.S. 2.8% 9 2/36













Tuna et al8 (2013) CT 0h & CXR 2-5h 83 18 g N.S. 8.4% 4.8% N.S. N.S. 8 4/83
Yamagami et al77 (2006) CT 0h & CXR 3h CT-ﬂuoroscopy 388 18-21 g 23 34.3% 18.6% N.S. N.S. 7 72/388
Yamauchi et al78 (2011) CT 0h & CXR 3h CT-ﬂuoroscopy 90 18 g 17 15.6% 0.0% N.S. 14.4% 6 0/90
Yeow et al79 (2004) CT 0h & CXR 4h 660 16-20 g cx N.S. 23.5% 2.1% 30.5% 3.9% 9 14/660






PNX, pneumothorax; PNX int, pneumothorax requiring intervention; NOS, Newcastle-Ottawa Scale; N.S., not specified; g, gauge; cx, coaxial needle; In
the forest plot the major complication rate with 95 % CI is plotted, the size of the circles represents the weight of each individual (sub) study as assigned
by the random effects model




















PNX PNX int. Pulm.Hem.
Hemop-
tysis
Covey et al40 (2004) Ct 0h & CXR 2h Yes 88 22 g N.S. 14.0% 5.0% N.S. N.S. 7 4/88
D'Alessandro et al41 (2007) CT 0h & CXR 4h No 594 19-22 g 47 17.0% 5.0% 4.0% 1.0% 7 29/594
Guimaraes et al42 (2010) CT 0h & CT 2-4h No 362 22 g 51.5 14.0% N.S. N.S. 2.0% 7 11/362
Kocijancic et al43 (2007) CT 0h & CXR 4h Yes 44 18 g 23 27.0% 5.0% 5.0% 2.0% 7 2/44
Kuban et al60 (2015) CT 0h & CXR 3h No 810 18-19 g cx 34.0% 16.0% N.S. N.S. 6 127/810
Langet al44 (2000) CT 0h & CXR 4h ABCControl No
50






16.0% N.S. N.S. RCT*
1/50
8/50
Laspas et al45 (2008) CT 0h & CT 1h Yes 409 21-23 g N.S. 4.0% 0.0% 2.0% 0.0% 7 1/409
Laurent et al7 (2000) CT 0h & CXR 4-6h Yes 125 18-19 g cx 35.8 20.0% 2.0% 14.0% 2.0% 9 3/125
Lee et al46 (2008) CT 0h & CXR 4h No 92 22 g 38 7.0% 0.0% 3.0% N.S. 7 0/92
Mesurolle et al47 (2003) CT 0h & CXR 1-2h No 85 18-21 g 29 26.0% 7.0% N.S. 5.0% 7 6/85
Nget al48 (2008) CT 0h & CXR 1h Yes 58 19 g 9 50.0% 9.0% N.S. N.S. 6 5/58
Noh et al49 (2009) CT 0h & CXR 4h & CXR 16h No 934 N.S. N.S. 25.0% N.S. N.S. N.S. 9 21/934
Priola et al50 (2010) CT 0h & CXR 3h Yes 321 20-21 g 37.2 27.0% 5.0% 29.0% 3.0% 9 18/321
Shantaveerappa et al51 (2002) CT 0h & CXR 4h Yes 158 22 g 33 27.0% 6.0% N.S. N.S. 9 11/158
Tuna et al8 (2013) CT 0h & CXR 2-5h No 22 18-22 g N.S. 18.0% 9.0% N.S. N.S. 8 2/22
Yazar et al52 (2013) CT 0h & CXR 2h Yes 316 22 g 50.5 9.0% 3.0% N.S. N.S. 9 9/316
Zhuanget al53 (2013) CT 0h & CXR 2h No 102 18-20 g 36 9.0% 0.0% 14.0% 1.0% 9 0/102
Total
0.0% 10.0% 20.0%4.4% 30.0%
Major Complicaon Rate
PNX, pneumothorax; PNX int, pneumothorax requiring intervention; NOS, Newcastle-Ottawa Scale; N.S., not specified; g, gauge; cx, coaxial needle;
ABC, autologous blood clot; none of the included studies for FNA procedures used CT-fluoroscopy; *Randomized Controlled Trial: no NOS score could
be determined. In the forest plot the major complication rate with 95 % CI is plotted, the size of the circles represents the weight of each individual (sub)
study as assigned by the random effects model
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Risk factors for complications
Table 6 lists all risk factors for complications with a p-val-
ue<0.20. For FNA procedures, larger needle diameter was a
risk factor for overall complications, with an odds ratio of 0.70
(95%CI: 0.55–0.89%; p=0.004) per gauge.When analyzing
the needle diameter categorically, an FNA needle gauge of 22
or higher resulted in decreased odds of overall complications
of 0.30 (95 % CI: 0.15–0.59 %; p<0.001) compared to lower
needle gauges. Figure 2 shows a scatter plot of the mean
needle size in FNA studies against the complication rate.
Increased mean lesion diameter decreased the risk of major
complications (OR: 0.97 per mm; 95 % CI: 0.95–0.99 %;
p= 0.017), and increased traversed lung parenchyma in-
creased the risk of major complication (OR: 1.05 per mm;
95 % CI: 1.00–1.11 %; p=0.035). The meta-analysis of core
biopsies did not reveal significant risk factors for overall com-
plications or for major complications.
Discussion
This meta-analysis determined the complication rate of CT-
guided core biopsy and FNA procedures and identified risk
factors for complications. For CT-guided core biopsy the
pooled rate of pneumothorax was 25.3 %, of pneumothorax
requiring intervention 5.6 %, of pulmonary haemorrhage
18.0 %, and of hemoptysis 4.1 %. For FNA procedures these
rates were lower, 18.8, 4.3, 6.4, and 1.7 %, respectively. This
difference was significant for all minor complications. For
FNA, larger needle diameter, smaller lesion size, and in-
creased traversed lung parenchyma were risk factors for
complications.
To our knowledge, no prior meta-analysis has studied the
complication rate of CT-guided lung biopsy. Two large studies
based on multi-centre procedures have been published.
Wiener et al. [54] estimated the complications rate of CT-
guided lung biopsy by analyzing two North American data-
bases containing 15,865 procedures and found that pneumo-
thorax occurred in 15.0 %, pneumothorax requiring chest tube
in 6.6 %, and pulmonary hemorrhage in 1.0 %. No distinction
was made between core biopsy and FNA. Tomiyama et al.
[55] published a survey of severe complications based on 9,
783 CT-guided lung biopsies in Japan and found
Table 4 Study, procedural, patient, and nodule characteristics of
included studies
Core biopsy (n= 32) FNA (n= 17)





Procedures (n) 8,133 4,620
Needle gauge 18.2 (1.2) 21.3 (1.7)
Use of coaxial needle 25/29 4/16
Use of biopsy device 26/29 N.A.
Use of CT-fluoroscopy 10/29 0/16
Gender
Male (n) 4,303 1,792
Female (n) 2,192 649
Patient age (years) 64.4 (2.9) 62.3 (3.8)
Pleural passes (n) 1.1 (0.4) 1.5
Nodule diameter (mm) 27.9 (7.8) 41.4 (10.0)
Distance skin-lesion (mm) 53.2 (13.3) 48.0 (6.0)
Traversed lung (mm) 16.6 (6.6) 14.1 (7.3)
Procedure time (min) 32 (5) N.S.
Operator experience (years) 10.1 (4.0) 8.0 (2.5)
Data are presented as number of studies or meanswith standard deviation.
Means are weighted by number of procedures. N.A. Not available
Fig. 2 Funnel plot of major complications of CT-guided core biopsy
Fig. 3 Funnel plot of major complications of CT-guided FNA
142 Eur Radiol (2017) 27:138–148
pneumothorax in 35 %. These results are quite discrepant.
Neither of these studies was included in this meta-analysis,
because they did not meet the inclusion criteria. In Quality
Improvement Guidelines for Percutaneous Needle Biopsy,
the SIR and ACR published an estimated pneumothorax rate
of 12–45 % and a chest tube placement rate of 2–15 % [56].
Again, this is a wide range, without differentiation between
core biopsy and FNA. However, our estimates of complica-
tion rate are approximately in the centre of their estimated
range.
Hemothorax rate could not be estimated reliably, because it
was reported in only six studies. Other rare major complica-
tions such as needle tract seeding, air embolism and death
were not reported by any of the included studies. Non-
included studies reported a range of 0.02–0.4 % for air embo-
lism [55, 57], 0.012–0.061 % for needle tract seeding [55, 58],
and 0.16 % for death [59]. In our selected studies (12,753
procedures in total) these complications could have been ex-
pected to occur, but such results are probably not as likely to
be published. Therefore, an underrepresentation of these very
rare and major complications is likely to exist in this meta-
analysis.
Comparing core biopsy with FNA is not straightforward.
Core biopsy and FNA have their own advantages when used
to diagnose lung lesions. Still, overall, complications occurred
less often in FNA procedures (OR: 0.50; 95 % CI: 0.35–
0.73 %). For major complications this correlation was not
significant, although a similar trend was visible in favour of
FNA. Included studies that compared FNA with core biopsy
[7, 8, 60] did not find significant differences in complication
rate, and in a systematic review comparing FNA with core
biopsy in lung cancer diagnosis, Yao et al. [9] reported incon-
sistent results concerning complication rates.
In this study, a smaller lesion size and an increased distance
traversed through lung parenchyma were found as risk factors
for major complications in case of FNA. Patient and nodule
characteristics most often mentioned as risk factors are older
age, presence of emphysema, smaller lesion size, increased
lesion depth, non-pleural contact, and smaller pleural-needle
angle [38, 39, 61–63]. However, in most included studies
Fig. 4 Scatter plot and regression
line with 95% confidence interval
of mean needle diameter in
relation to overall complication
rate in FNA procedures. The size
of the circles represents the
relative weight of the study as
assigned by the random effects
model
Table 5 Pooled complication rates of CT-guided transthoracic lung biopsy
Complication rates (95 % confidence intervals) Odds ratioa p-value
Core biopsy FNA
Pneumothorax 25.3 % (22.2–28.6 %) 18.8 % (14.6–23.9 %) 0.69 (0.50–0.96) 0.027
Pneumothorax intervention 5.6 % (4.3–7.3 %) 4.3 % (2.7–7.0 %) 0.76 (0.48–1.37) 0.430
Pulmonary haemorrhage 18.0 % (13.4–23.8 %) 6.4 % (2.5–15.2 %) 0.33 (0.15–0.72) 0.005
Hemoptysis 4.1 % (2.8–6.1 %) 1.7 % (0.9–3.1 %) 0.38 (0.17–0.85) 0.019
Overall complications 38.8 % (34.3–43.5 %) 24.0 % (18.2–30.8 %) 0.50 (0.35–0.73) <0.001
Major complication 5.7 % (4.4–7.4 %) 4.4 % (2.7–7.0 %) 0.80 (0.48–1.36) 0.416
a Core biopsy is reference
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these characteristics are only reported as a mean, and compli-
cations are not stratified based on these variables. Therefore,
this meta-analysis is not ideal to identify patient- and nodule-
specific risk factors.
In contrast, a meta-analysis can find risk factors in study-
specific characteristics such as needle size, use of coaxial nee-
dle, number of biopsies, use of CT-fluoroscopy, on-site cytol-
ogy, number of operators, operator experience, and institute
frequency—factors that would be hard to identify in a single-
cohort/institute, retrospective study. There was no difference
in risk of complication between high and low volume centres.
Also, no significant correlation between the sample size, num-
ber of biopsies, number of operators, operator experience, use
of coaxial needle, CT-fluoroscopy, on-site cytology, or biopsy
site down technique and (major) complication rate was found.
Only papers using CT guidance (conventional and/or CT-
fluoroscopy) were included in this study. Conventional CT
guidance offers the advantage of a simulated 3D view making
it easy to look along the needle path. Also, there is no ionizing
radiation exposure for the operator. CT-fluoroscopy offers the
advantages of a near real-time imaging feedback as the needle
is being inserted. It is, however, associated with an increased
patient and operator dose [22, 64, 65]. These methods can be
used interchangeably, e.g. starting with conventional CT guid-
ance and switching to CT-fluoroscopy when the lung lesion
proves difficult to reach because of patient respiration. For
core biopsy we found a trend that suggested CT-fluoroscopy
might result in a higher major complication rate (OR: 1.62;
95 % CI: 0.81–3.23 %; p = 0.171). CT-fluoroscopy is
generally reported to have a lower complication rate due to
shorter procedure time and fewer needle passes [22, 33, 64].
However, if CT-fluoroscopy is indeed used more frequently in
cases of hard-to-reach lesions, it could potentially bias the
results, as it generally takes longer to sample these. Lastly, it
should be noted that none of the included studies used CT-
fluoroscopy for FNA.
Intuitively, operator experience is thought to influence
complication rate. In a large single-cohort study, Yeow et al.
[38] reported operator experience as the third major risk factor
for pneumothorax. In our meta-analysis only a few papers
reported the operator experience (core biopsy: n=10; FNA:
n=3). Because of the low number of studies reporting opera-
tor experience, and because only overall mean operator expe-
rience was reported (so not per operator), it was not possible to
further study this potential risk factor in our meta-analysis.
The use of coaxial needles has the advantage of decreasing
the number of pleural passes. However, it results in a
prolonged connection with the pleura which might lead to
increased parenchymal damage due to respiratory motion.
Also, it increases the outer needle diameter. None of the in-
cluded studies specifically investigated the effect of coaxial
needles on complication rate. Two other studies did [66, 67],
but found no significant correlation. In meta-regression there
were trends for coaxial needles towards an increase in overall
complications for core biopsy (OR: 1.37; 95 % CI: 0.88–
2.12 %; p=0.164), and for FNA (OR: 1.87; 95 % CI: 0.80–
4.33 %; p = 0.146), but none of these correlations were
significant.
Table 6 Risk factors for
complications and major
complications for CT-guided
transthoracic core biopsy and
FNA of lung lesions
Studies (n) Procedures (n) Odds ratio (95 % CI) p-value
Core biopsy: Overall complications
Coaxial needle 32 8,133 1.37 (0.88–2.12) 0.164
Mean lesion size 32 8,133 0.98 (0.94–1.01) 0.185
Use of biopsy device 32 8,133 1.44 (0.91–2.27) 0.115
Core biopsy: Major complications
CT-fluoroscopy 32 8,133 1.62 (0.81–3.23) 0.171
Mean patient age 32 8,133 1.09 (0.98–1.21) 0.124
FNA: Overall complications
Mean needle gauge 17 4,084 0.70 (0.55–0.89) 0.004
Needle diameter >= 22 gauge 17 4,084 0.30 (0.15–0.59) <0.001
Mean lesion size 12 2,357 0.97 (0.93–1.00) 0.073
Mean number of biopsy samples 6 1.36 (0.50–3.71) 0.549
FNA: Major complications
Mean needle gauge 17 4,084 0.82 (0.64–0.96) 0.106
Needle diameter >= 22 gauge 17 4,084 0.58 (0.27–1.27) 0.172
Traversed lung (mm) 4 797 1.05 (1.00–1.11) 0.035
Coaxial needle 17 4,084 1.87 (0.80–4.33) 0.146
Lesion size (mm) 12 2,357 0.97 (0.95–0.99) 0.017
Number of operators 10 2,496 1.29 (0.97–1.71) 0.079
Only potential risk factors with a significant of p< 0.20 are listed in this table
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The biopsy site down technique has been cause for some
debate; although some papers report no difference in compli-
cation rate when repositioning the patient after the procedure
[64], others have demonstrated a considerable reduction in
pneumothorax and/or chest tube placement rate in case of
patient repositioning [65]. O’Neill et al. [66] suggested that
the critical factor for success is to immediately roll the patient
over after biopsy, calling it rapid needle-out patient-rollover.
Kim et al. [67] recently reported a significant reduction of
chest tube placement in cone beam CNB in a retrospective
study among 1,191 patients, using similar technique. None
of the papers included in this meta-analysis, using the biopsy
site down technique, mentioned to roll the patients over im-
mediately, which is why this correlation could not be evaluat-
ed. However, Kinoshita et al. [26] have been positioning pa-
tients (n=147) with the biopsy site downwards during the
procedure, using a special table, after which they stayed in
biopsy site down position for approximately 15 min. They
report a considerable drop in pneumothorax rate compared
to the standard procedure, which also suggests that patient
(re) positioning in the initial minutes after, or even during,
biopsy is critical.
For overall complications in FNA, the use of larger
needles was a risk factor. Per increased needle gauge, the
risk decreased by 30 % (OR: 0.70; 95 % CI: 0.55–0.89 %).
According to the guidelines of the SIR [56] only procedures
performed with 22 or higher gauge needles should be con-
sidered fine needle aspiration. When categorized according
to this definition, the use of fine needles compared to larger
needles decreased the risk of complications by 70 % (OR:
0.30; 95 % CI: 0.15–0.59 %). For major complications,
however, needle size was not a significant risk factor. For
core biopsy procedures no significant risk factors were
found.
Studies were only included in this meta-analysis if they
reported adequate monitoring of complications. Although that
resulted in the exclusion of 75 studies, it made sure that no
studies were included that underreported their complication
rate. Because chest radiography has demonstrated to miss a
significant number of pneumothorax cases after CT-guided
lung biopsy compared to CT [68], an initial control CT scan
was a requirement for inclusion. Also, at least additional chest
radiography 2 to 4 h after the procedure was required, because
studies have shown that initially covert pneumothorax detect-
ed by delayed chest radiograph sometimes does require chest
tube insertion [49, 69]. Another inclusion criterion was the
reporting of complications of at least 50 procedures, resulting
in the exclusion of 32 studies. Excluding smaller studies may
bias results, as less experienced departments can be expected
to have a higher complication rate. The funnel plots of includ-
ed studies show no clear asymmetry, and regression analysis
showed no correlation between sample size and complication
rate, so we do not expect the exclusion of small studies to have
biased the results. However, since small studies were not in-
cluded in the analyses, this cannot be excluded with certainty.
We investigated potential sources of heterogeneity, but
much of the variance between studies could not be explained.
Therefore, a random-effects model was used to pool compli-
cation rates. This makes the estimates more reliable as it fa-
vours larger studies relatively less, compared to a fixed effects
model. Also, outliers do not get weighted as heavily as they
otherwise would. Overall, we expect that the provided pooled
complication rates are accurate estimates of actual complica-
tion rates.
This study has some limitations. It was not designed to
compare specifically the complication rates of core biopsy
with FNA. Most included studies only report complications
of one method, so usually no controls in the same population
are available. Also, although the quality of the studies includ-
ed in both groups is generally high according to the NOS
score, there are potential sources of bias within the studies.
In the past, FNAwould be preferred over core biopsy for small
nodules, because core samples of high quality were consid-
ered hard to obtain. It has previously been shown that smaller
lesions are more likely to result in complications, which might
cause the pooled complication rates of core biopsy and FNA
to be biased [24, 40]. However, in our meta-analysis the mean
lesion diameter for core biopsy was significantly smaller than
for FNA procedures (28 vs. 42 mm). Although lesion size was
not a significant risk factor for complications of core biopsy,
this difference could be a potential confounder. Another po-
tential source of within study bias could be in the selection of
sampling techniques in case additional histological subtyping
is required for targeted therapy. In those cases core biopsy is
often preferred, and these patients can be expected to have a
higher comorbidity resulting in a higher complication rate.
Papers were only included if complications of FNA and
core biopsy were presented separately. Sometimes both tech-
niques are used in the same setting in an effort to increase the
diagnostic performance, which can inadvertently lead to a
higher rate of complications [70–72]. This study cannot draw
conclusions as to whether or not combined usage of sampling
techniques indeed increases the complication rate.
Lastly, this study could not determine the rate of complica-
tions that occur infrequently or require a long term follow-up of
the patient, such as death, air embolism and needle tract seeding.
In the specific context of diagnostic work-up of lung nod-
ules detected in CT-screening FNA should be favoured over
core biopsy. This is especially the case for 22-gauge needles,
with which the risk of complications decreases greatly. Also,
studies have shown that diagnostic yield does not decrease
when using smaller FNA needles [73], and advances in
FNA cytology have enabled subtyping of lung cancer in cy-
tological material [74].
It should be considered that a smaller lesion size is a risk
factor for major complications, and that nodules detected by
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lung cancer CT-screening, needing work-up, are generally
smaller in size [75]. However, factors such as younger age
and less comorbidity that can be expected in screening pa-
tients will have a beneficial effect on the expected complica-
tion rate. Overall, the pooled complication rate determined in
this meta-analysis cannot be assumed to be similar in screen-
detected nodules.
In order to compare the complications of core biopsy and
FNA properly, only randomized controlled trials or even only
prospective studies comparing both techniques should be in-
cluded in the meta-analysis. However, randomized controlled
trials comparing these techniques have not been published,
and only two prospective studies compared complication
rates. Therefore, well-designed randomized controlled trials
would be recommended to definitively compare the safety of
CT-guided lung core biopsy and FNA.
Conclusion
For CT-guided lung biopsy the overall complication rate is
acceptable and the major complication rate is low.Minor com-
plications occur more often with core biopsy compared to
FNA. For major complications this difference is not signifi-
cant. In cases of FNA, larger needle size is a risk factor for
overall complications, and risk factors for major complica-
tions are smaller lesion size and increased traversed lung pa-
renchyma. CT-guided lung biopsy, and particularly FNAwith
small needles, can be an important diagnostic tool, with a low
major complication rate.
Acknowledgments The scientific guarantor of this publication is M.
Oudkerk. The authors of thismanuscript declare no relationships with any
companies, whose products or services may be related to the subject
matter of the article. The authors state that this work has not received
any funding. One of the authors has significant statistical expertise.
Institutional Review Board approval was not required because this
meta-analysis does not involve human subjects. Methodology: retrospec-
tive, observational, performed at one institution.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Moyer VA (2014) Screening for lung cancer: U.S. Preventive ser-
vices task force recommendation statement. Ann Intern Med 160:
330–8
2. Kauczor H-U, Bonomo L, Gaga M et al (2015) ESR/ERS white
paper on lung cancer screening. Eur Respir J 46:28–39
3. Cardella JF, Bakal CW, Bertino RE et al (1996) Quality improve-
ment guidelines for image-guided percutaneous biopsy in adults:
society of cardiovascular & interventional radiology standards of
practice committee. J Vasc Interv Radiol 7:943–6
4. Manhire A, Charig M, Clelland C et al (2003) Guidelines for radio-
logically guided lung biopsy. Thorax 58:920–36
5. Beslic S, Zukic F, Milisic S (2012) Percutaneous transthoracic CT
guided biopsies of lung lesions; fine needle aspiration biopsy versus
core biopsy. Radiol Oncol 46:19–22
6. Yeow KM, Tsay PK, Cheung YC, Lui KW, Pan KT, Chou AS
(2003) Factors affecting diagnostic accuracy of CT-guided coaxial
cutting needle lung biopsy: retrospective analysis of 631 proce-
dures. J Vasc Interv Radiol 14:581–8
7. Laurent F, Latrabe V, Vergier B, Michel P (2000) Percutaneous CT-
guided biopsy of the lung: comparison between aspiration and au-
tomated cutting needles using a coaxial technique. Cardiovasc
Intervent Radiol 23:266–72
8. Tuna T, Ozkaya S, Dirican A, Findik S, Atici AG, Erkan L (2013)
Diagnostic efficacy of computed tomography-guided transthoracic
needle aspiration and biopsy in patients with pulmonary disease.
Oncol Targets Ther 6:1553–7
9. Yao X, Gomes MM, Tsao MS, Allen CJ, Geddie W, Sekhon H
(2012) Fine-needle aspiration biopsy versus core-needle biopsy in
diagnosing lung cancer: a systematic review. Curr Oncol 19:e16–27
10. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement. PLoS Med 6:e1000097
11. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, LososM PT.
The Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. Available from: URL:
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
cited 2016 Jan 4
12. Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of
interventional radiology clinical practice guidelines. J Vasc Interv
Radiol 14:S199–202
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003)
Measuring inconsistency in meta-analyses. BMJ 327:557–60
14. Besir FH, Altin R, Kart L et al (2011) The results of computed
tomography guided tru-cut transthoracic biopsy: complications
and related risk factors. Wien Klin Wochenschr 123:79–82
15. Billich C,Muche R, Brenner G et al (2008) CT-guided lung biopsy:
incidence of pneumothorax after instillation of NaCl into the biopsy
track. Eur Radiol 18:1146–52
16. Bozbas SS, Akcay S, Ergur FO, Aytekin C, Savas BS, Ozturk EF
(2010) Transthoracic lung and mediastinal biopsies obtained with
the Tru-Cut technique: 10 years’ experience. Turkish J Med Sci 40:
495–501
17. Braak SJ, Herder GJ, van Heesewijk JP, van Strijen MJ (2012)
Pulmonary masses: initial results of cone-beam CT guidance with
needle planning software for percutaneous lung biopsy. Cardiovasc
Intervent Radiol 35:1414–21
18. Brandén E, Wallgren S, Högberg H, Koyi H (2014) Computer
tomography-guided core biopsies in a county hospital in Sweden:
Complication rate and diagnostic yield. Ann Thorac Med 9:149–53
19. Chakrabarti B, Earis JE, Pandey R et al (2009) Risk assessment of
pneumothorax and pulmonary haemorrhage complicating percuta-
neous co-axial cutting needle lung biopsy. Respir Med 103:449–55
20. Lim C-S, Tan L-E, Wang J-Y et al (2014) Risk factors of pneumo-
thorax after CT-guided coaxial cutting needle lung biopsy through
aerated versus nonaerated lung. J Vasc Interv Radiol 25:1209–17
21. Hanninen EL, Vogl TJ, Ricke J, Felix R, Lopez Hanninen E (2001)
CT-guided percutaneous core biopsies of pulmonary lesions.
Diagnostic accuracy, complications and therapeutic impact. Acta
Radiol 42:151–5
146 Eur Radiol (2017) 27:138–148
22. Heck SL, Blom P, Berstad A (2006) Accuracy and complications in
computed tomography fluoroscopy-guided needle biopsies of lung
masses. Eur Radiol 16:1387–92
23. Hiraki T, Mimura H, Gobara H et al (2010) Incidence of and risk
factors for pneumothorax and chest tube placement after CT
fluoroscopy-guided percutaneous lung biopsy: retrospective analy-
sis of the procedures conducted over a 9-year period. AJR Am J
Roentgenol 194:809–14
24. Khan MF, Straub R, Moghaddam SR et al (2008) Variables affect-
ing the risk of pneumothorax and intrapulmonal hemorrhage in CT-
guided transthoracic biopsy. Eur Radiol 18:1356–63
25. Kim TJ, Lee JH-H, Lee CT-T et al (2008) Diagnostic accuracy of
CT-guided core biopsy of ground-glass opacity pulmonary lesions.
AJR Am J Roentgenol 190:234–9
26. Kinoshita F, Kato T, Sugiura K et al (2006) CT-guided transthoracic
needle biopsy using a puncture site-down positioning technique.
AJR Am J Roentgenol 187:926–32
27. Laurent F, Latrabe V, Vergier B, Montaudon M, Vernejoux JM,
Dubrez J (2000) CT-guided transthoracic needle biopsy of pulmo-
nary nodules smaller than 20 mm: results with an automated 20-
gauge coaxial cutting needle. Clin Radiol 55:281–7
28. Loubeyre P, Copercini M, Dietrich PY (2005) Percutaneous CT-
guided multisampling core needle biopsy of thoracic lesions. Am
J Roentgenol 185:1294–8
29. Maataoui A, Vogl TJ, Jacobi V, Khan MF (2012) Diagnostic accu-
racy of CT readings on coin lesions in the lung as compared with
transthoracic CT-guided needle biopsy results. Pneumologie 66:
432–6
30. Mendiratta-Lala M, Sheiman R, Brook OR, Gourtsoyianni S,
Mahadevan A, Siewert B (2014) CT-guided core biopsy and per-
cutaneous fiducial seed placement in the lung: can these procedures
be combined without an increase in complication rate or decrease in
technical success? Eur J Radiol
31. Montaudon M, Latrabe V, Pariente A, Corneloup O, Begueret H,
Laurent F (2004) Factors influencing accuracy of CT-guided
percutaneous biopsies of pulmonary lesions. Eur Radiol 14:
1234–40
32. Patel MV, Ahmed O, Jilani D, Zangan S (2014) Computed
tomography-guided percutaneous lung biopsy: impact of lesion
proximity to diaphragm on biopsy yield and pneumothorax rate. J
Thorac Imaging 29:344–9
33. Prosch H, Stadler A, Schilling M et al (2012) CT fluoroscopy-
guided vs. multislice CT biopsy mode-guided lung biopsies: accu-
racy, complications and radiation dose. Eur J Radiol 81:1029–33
34. Satoh S, Ohdama S, Matsubara O, Okochi Y, Tanaka R, Kimula Y
(2005) CT-guided automated cutting needle biopsy by a combined
method for accurate specific diagnosis of focal lung lesions. Radiat
Med 23:30–6
35. Schoth F, Plumhans C, Kraemer N et al (2010) Evaluation of an
interactive breath-hold control system in CT-guided lung biopsy.
Röfo 182:507–11
36. Tachibana K, Nakazato Y, Tsuchida S et al (2013) Immediate cy-
tology improves accuracy and decreases complication rate in real-
time computed tomography-guided needle lung biopsy. Diagn
Cytopathol 41:1063–8
37. Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T,
Nishimura T (2006) Duration of pneumothorax as a complication
of CT-guided lung biopsy. Australas Radiol 50:435–41
38. Yeow K-M, Su I-H, Pan K-T et al (2004) Risk factors of pneumo-
thorax and bleeding: multivariate analysis of 660 CT-guided coaxial
cutting needle lung biopsies. Chest 126:748–54
39. Yildirim E, Kirbas I, Harman A et al (2009) CT-guided cutting
needle lung biopsy using modified coaxial technique: factors
effecting risk of complications. Eur J Radiol 70:57–60
40. Covey AM, Gandhi R, Brody LA, Getrajdman G, Thaler HT,
Brown KT (2004) Factors associated with pneumothorax and
pneumothorax requiring treatment after percutaneous lung biopsy
in 443 consecutive patients. J Vasc Interv Radiol 15:479–83
41. D’Alessandro V, Parracino T, Stranieri A et al (2007) Computed-
tomographic-guided biopsy of thoracic nodules: a revision of 583
lesions. Clin Ter 158:509–13
42. Guimaraes MD, Andrade MQ, Fonte AC, Benevides G, Chojniak
R, Gross JL (2010) Predictive complication factors for CT-guided
fine needle aspiration biopsy of pulmonary lesions. Clin (Sao
Paulo) 65:847–50
43. Kocijancic I, Kocijancic K (2007) CT-guided percutaneous trans-
thoracic needle biopsy of lung lesions - 2-Year experience at the
Institute of Radiology in Ljubljana. Radiol Oncol 41:99–106
44. Lang EK, Ghavami R, Schreiner VC, Archibald S, Ramirez J
(2000) Autologous blood clot seal to prevent pneumothorax at
CT-guided lung biopsy. Radiology 216:93–6
45. Laspas F, Roussakis A, Efthimiadou R, Papaioannou D,
Papadopoulos S, Andreou J (2008) Percutaneous CT-guided fine-
needle aspiration of pulmonary lesions: results and complications
in 409 patients. J Med Imaging Radiat Oncol 52:458–62
46. Lee YS, Jin GY, Han YM, Chung MJ, Park HS (2008) Computed
tomography-guided transthoracic needle aspiration biopsy of
intrapulmonary lesions: utility of a liquid-based cytopreparatory
technique. Acta Cytol 52:665–70
47. Mesurolle B,Mignon F, Meingan P, Domenge C, Vasile M, Sigal R
(2003) Head and neck cancer patients with pulmonary nodules:
value and role of CT-guided transthoracic needle aspiration biop-
sies. Head Neck 25:889–94
48. Ng YL, Patsios D, Roberts H et al (2008) CT-guided percutaneous
fine-needle aspiration biopsy of pulmonary nodules measuring
10 mm or less. Clin Radiol 63:272–7
49. Noh TJ, Lee CH, Kang YA et al (2009) Chest computed tomogra-
phy (CT) immediately after CT-guided transthoracic needle aspira-
tion biopsy as a predictor of overt pneumothorax. Korean J Intern
Med 24:343–9
50. Priola AM, Priola SM, Cataldi A et al (2010) Diagnostic accuracy
and complication rate of CT-guided fine needle aspiration biopsy of
lung lesions: a study based on the experience of the cytopathologist.
Acta Radiol 51:527–33
51. Shantaveerappa HN, Mathai MG, Byrd RP Jr, Karnad AB, Mehta
JB, Roy TM (2002) Intervention in patients with pneumothorax
immediately following CT-guided fine needle aspiration of pulmo-
nary nodules. Med Sci Monit 8:CR401–4
52. Yazar E, Secik F, Yildiz P (2013) Does repeating CT-guided trans-
thoracic fine needle aspiration increase diagnostic yield and com-
plication rate? a single institution experience. Iran J Radiol 10:56–
60
53. Zhuang YP, Wang HY, Zhang J, Feng Y, Zhang L (2013)
Diagnostic accuracy and safety of CT-guided fine needle aspiration
biopsy in cavitary pulmonary lesions. Eur J Radiol 82:182–6
54. Wiener RS, Schwartz LM, Woloshin S, Welch HG (2011)
Population-based risk for complications after transthoracic needle
lung biopsy of a pulmonary nodule: an analysis of discharge re-
cords. Ann Intern Med 155:137–44
55. Tomiyama N, Yasuhara Y, Nakajima Y et al (2006) CT-guided
needle biopsy of lung lesions: a survey of severe complication
based on 9783 biopsies in Japan. Eur J Radiol 59:60–4
56. Gupta S, Wallace MJ, Cardella JF, Kundu S, Miller DL, Rose SC
(2010) Quality improvement guidelines for percutaneous needle
biopsy. J Vasc Interv Radiol 21:969–75
57. Hiraki T, Fujiwara H, Sakurai J et al (2007) Nonfatal systemic air
embolism complicating percutaneous CT-guided transthoracic nee-
dle biopsy: four cases from a single institution. Chest 132:684–90
58. Ayar D, Golla B, Lee JY, Nath H (1998) Needle-track metastasis
after transthoracic needle biopsy. J Thorac Imaging 13:2–6
59. Freund MC, Petersen J, Goder KC, Bunse T, Wiedermann F,
Glodny B (2012) Systemic air embolism during percutaneous core
Eur Radiol (2017) 27:138–148 147
needle biopsy of the lung: frequency and risk factors. BMC Pulm
Med 12:2
60. Kuban JD, Tam AL, Huang SY, et al (2015) The effect of needle
gauge on the risk of pneumothorax and chest tube placement after
percutaneous computed tomographic (CT)-guided lung biopsy.
Cardiovasc Interv Radiol
61. Priola AM, Novello S, Priola SM et al (2007) Factors effecting risk
of pneumothorax (PNX) in CT-guided transthoracic needle biopsy
of lung lesions: results of 708 consecutive procedures. J Thorac
Oncol 2:S362
62. Choi CM, Um SW, Yoo CG et al (2004) Incidence and risk factors
of delayed pneumothorax after transthoracic needle biopsy of the
lung. Chest 126:1516–21
63. Saji H, Nakamura H, Tsuchida T et al (2002) The incidence and the
risk of pneumothorax and chest tube placement after percutaneous
CT-guided lung biopsy: the angle of the needle trajectory is a novel
predictor. Chest 121:1521–6
64. Kim GR, Hur J, Lee SM et al (2011) CT fluoroscopy-guided lung
biopsy versus conventional CT-guided lung biopsy: a prospective
controlled study to assess radiation doses and diagnostic perfor-
mance. Eur Radiol 21:232–9
65. Prosch H, Schilling M, Stadlert A, Eisenhuber E, Oschatz E,
Mostbeck G (2009) CT-fluoroscopy guided versus multislice ct
biopsy mode guided lung biopsies: Accuracy, complications and
radiation dose. J Thorac Imaging 24:w25
66. Kucuk CU, Yilmaz A, Akkaya E (2004) Computed tomography-
guided transthoracic fine-needle aspiration in diagnosis of lung can-
cer: a comparison of single-pass needle and multiple-pass coaxial
needle systems and the value of immediate cytological assessment.
Respirology 9:392–6
67. Nour-Eldin N-EA, Alsubhi M, Emam A, et al (2015)
Pneumothorax complicating coaxial and non-coaxial CT-guided
lung biopsy: comparative analysis of determining risk factors and
management of pneumothorax in a retrospective review of 650
patients. Cardiovasc Interv Radiol
68. Bungay HK, Berger J, Traill ZC, Gleeson FV (1999) Pneumothorax
post CT-guided lung biopsy: a comparison between detection on
chest radiographs and CT. Br J Radiol 72:1160–3
69. Branden E,Wallgren S, Koyi H (2011) CT guided core biopsies in a
county hospital in Sweden - Diagnostic yield and complication rate.
Chest 140(4)
70. Yamagami T, Iida S, Kato T, Tanaka O, Nishimura T (2003)
Combining fine-needle aspiration and core biopsy under CT fluo-
roscopy guidance: a better way to treat patients with lung nodules?
AJR Am J Roentgenol 180:811–5
71. Gong Y, Sneige N, Guo M, Hicks ME, Moran CA (2006)
Transthoracic fine-needle aspiration vs concurrent core needle bi-
opsy in diagnosis of intrathoracic lesions: a retrospective compar-
ison of diagnostic accuracy. Am J Clin Pathol 125:438–44
72. Klein JS, Salomon G, Stewart EA (1996) Transthoracic needle
biopsy with a coaxially placed 20-gauge automated cutting needle:
results in 122 patients. Radiology 198:715–20
73. Moore W, Sawas A, Lee C, Ferretti J (2011) Needle gauge and
cytological yield in CT-guided lung biopsy. ISRN Pulmonol
74. Hasanovic A, RekhtmanN, Sigel CS,Moreira AL (2011)Advances
in fine needle aspiration cytology for the diagnosis of pulmonary
carcinoma. Patholog Res Int 2011:897292
75. Horeweg N, van Rosmalen J, Heuvelmans MA et al (2014) Lung
cancer probability in patients with CT-detected pulmonary nodules:
a prespecified analysis of data from the NELSON trial of low-dose
CT screening. Lancet Oncol 15:1332–41
148 Eur Radiol (2017) 27:138–148
